This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from several Israeli institutions conducted a retrospective study of infants with isolated sensorineural hearing loss (SNHL) from congenital cytomegalovirus (cCMV) to assess the efficacy of valganciclovir on hearing status. Infants were included if they (a) had cCMV, defined as a positive urine culture or polymerase chain reaction on a specimen taken during the first 2 weeks of life; (b) were followed up for at least 1 year at the study hospital from 2005 to 2017; (c) had a pathologic hearing evaluation at birth by means of brainstem auditory evoked response (BAER); (d) did not have other central nervous system or non-central nervous system manifestations of cCMV; and (e) had started in the first 12 weeks of life either IV ganciclovir at 5 mg/kg/day for …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.